Interest of Drug Reconciliation to Ensure the Continuity of the Treatment at Discharge (ICOCON)

Centre Hospitalier le Mans

Status: Unknown

Conditions: Hospitalized Patient

Treatments: Other: Drug reconciliation

Study type: Interventional

Funder types: Other

Identifiers

NCT05062655

CHM-2021/S21/09

Details and patient eligibility

About

From a regulatory point of view, medication reconciliation is a necessary process to ensure safe medication management for patients. According to national studies and the international scientific literature, the information received by patients and health professionals at discharge from hospital is insufficient.

Medication reconciliation at discharge reduces medication errors and rehospitalisation, but few studies have been conducted on the impact of a coordinated and reliable care pathway on medication continuity.

The iCoCon study will enable a new healthcare organisation to be set up in order to improve the quality of the patient pathway and the patient's medication management.

This new organisation is part of the policy of continuous improvement of the quality and safety of care

Enrollment: 130 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• hospitalized patient
• Patient with a drug treatment with a particular mode of supply
• Paediatric patient or an adult patient.
• First inpatient stay over the inclusion period from late 2021 to late 2022

Exclusion criteria

• Patient under curatorship or guardianship
• Patient residing abroad
• No free, informed and written consent obtained

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

130 participants in 2 patient groups

Drug reconciliation

Experimental group

Description:

Drug reconciliation and transmission to pharmacist

Treatment:

Other: Drug reconciliation

standard

No Intervention group